Gene delivery of medium chain acyl-coenzyme A dehydrogenase induces physiological cardiac hypertrophy and protects against pathological remodelling

Clinical Science

Volumn 132, Issue 3, 2018, Pages 381-397

  Bernardo, Bianca C ^a,b   Weeks, Kate L ^a   Pongsukwechkul, Thawin ^a,b   Gao, Xiaoming ^a   Kiriazis, Helen ^a   Cemerlang, Nelly ^a   Boey, Esther J H ^a   Tham, Yow Keat ^a,c   Johnson, Chad J ^d   Qian, Hongwei ^a   Du, Xiao Jun ^a,c   Gregorevic, Paul ^a,b,c,e   McMullen, Julie R ^a,c  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d BURNET INSTITUTE   (Australia)

^e UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS VECTOR; COMPLEMENTARY DNA; FATTY ACID; MEDIUM CHAIN ACYL COENZYME A DEHYDROGENASE; PHOSPHATIDYLINOSITOL 3 KINASE; RNA; PROTECTIVE AGENT;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAPILLARY DENSITY; CARDIAC MUSCLE CELL; CONTROLLED STUDY; FATTY ACID OXIDATION; GENE EXPRESSION; HEART DISEASE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE WALL; HEART MUSCLE FIBROSIS; HEART MUSCLE METABOLISM; HEART PROTECTION; HEART RATE; HEART SIZE; HEART STRESS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEK293T CELL LINE; HUMAN; HUMAN CELL; MALE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; NORTHERN BLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSTHORACIC ECHOCARDIOGRAPHY; VIRAL GENE DELIVERY SYSTEM; VIRUS RECOMBINANT; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CARDIOMEGALY; DISEASE MODEL; DRUG EFFECT; GENE THERAPY; GENETICS; PATHOLOGY;

ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; GENETIC THERAPY; HEART FAILURE; MALE; MICE, INBRED C57BL; MYOCARDIUM; MYOCYTES, CARDIAC; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTECTIVE AGENTS;

EID: 85046549015     PISSN: 01435221     EISSN: 14708736     Source Type: Journal    
DOI: 10.1042/CS20171269     Document Type: Article

References (53)

1. Braunwald, E. (2015) The war against heart failure: the Lancet lecture. Lancet North Am. Ed. 385, 812-824, https://doi.org/10.1016/S0140-6736(14)61889-4
2. Mozaffarian, D., Benjamin, E.J., Go, A.S., Arnett, D.K., Blaha, M.J., Cushman, M. et al. (2015) Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation 131, e29-322, https://doi.org/10.1161/CIR.0000000000000157
3. Liu, L. and Eisen, H.J. (2014) Epidemiology of heart failure and scope of the problem. Cardiol. Clin. 32, 1-8, https://doi.org/10.1016/j.ccl.2013.09.009
4. McMullen, J.R., Amirahmadi, F., Woodcock, E.A., Schinke-Braun, M., Bouwman, R.D., Hewitt, K.A. et al. (2007) Protective effects of exercise and phosphoinositide 3-kinase(p110alpha) signaling in dilated and hypertrophic cardiomyopathy. Proc. Natl. Acad. Sci. U.S.A. 104, 612-617, https://doi.org/10.1073/pnas.0606663104
5. McMullen, J.R., Shioi, T., Zhang, L., Tarnavski, O., Sherwood, M.C., Kang, P.M. et al. (2003) Phosphoinositide 3-kinase(p110alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A. 100, 12355-12360, https://doi.org/10.1073/pnas.1934654100
6. Prakoso, D., De Blasio MJ, Qin C, Rosli, S., Kiriazis, H., Qian, H. et al. (2017) Phosphoinositide 3-kinase (p110a) gene delivery limits diabetes-induced cardiac NADPH oxidase and cardiomyopathy in a mouse model with established diastolic dysfunction. Clin. Sci. (Lond.) 131, 1345-1360, https://doi.org/10.1042/CS20170063
7. Pretorius, L., Du, X.-J., Woodcock, E.A., Kiriazis, H., Lin, R.C.Y., Marasco, S. et al. (2009) Reduced phosphoinositide 3-kinase (p110alpha) activation increases the susceptibility to atrial fibrillation. Am. J. Pathol. 175, 998-1009, https://doi.org/10.2353/ajpath.2009.090126
8. Ritchie, R.H., Love, J.E., Huynh, K., Bernardo, B.C., Henstridge, D.C., Kiriazis, H. et al. (2012) Enhanced phosphoinositide 3-kinase(p110alpha) activity prevents diabetes-induced cardiomyopathy and superoxide generation in a mouse model of diabetes. Diabetologia 55, 3369-3381, https://doi.org/10.1007/s00125-012-2720-0
9. Weeks, K.L., Gao, X., Du, X.J., Boey, E.J., Matsumoto, A., Bernardo, B.C. et al. (2012) Phosphoinositide 3-kinase p110alpha is a master regulator of exercise-induced cardioprotection and PI3K gene therapy rescues cardiac dysfunction. Circ. Heart Fail. 5, 523-534, https://doi.org/10.1161/CIRCHEARTFAILURE.112.966622
10. Lin, R.C.Y., Weeks, K.L., Gao, X.-M., Williams, R.B.H., Bernardo, B.C., Kiriazis, H. et al. (2010) PI3K(p110a) protects against myocardial infarction-induced heart failure/ Identification of PI3K-regulated miRNAs and mRNAs. Arterioscler. Thromb. Vasc. Biol. 30, 724-732, https://doi.org/10.1161/ATVBAHA.109.201988
11. Bernardo, B.C., Ooi, J.Y.Y., Weeks, K.L., Patterson, N.L. and McMullen, J.R. (2017) Understanding key mechanisms of exercise-induced cardiac protection to mitigate disease: current knowledge and emerging concepts. Physiol. Rev. 98, 419-475
12. Oudit, G.Y., Crackower, M.A., Eriksson, U., Sarao, R., Kozieradzki, I., Sasaki, T. et al. (2003) Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. Circulation 108, 2147-2152, https://doi.org/10.1161/01.CIR.0000091403.62293.2B
13. McMullen, J.R. and Jay, P.Y. (2007) PI3K(p110alpha) inhibitors as anti-cancer agents: minding the heart. Cell Cycle 6, 910-913, https://doi.org/10.4161/cc.6.8.4124
14. Vanhaesebroeck, B., Guillermet-Guibert, J., Graupera, M. and Bilanges, B. (2010) The emerging mechanisms of isoform-specific PI3K signalling. Nat. Rev. Mol. Cell Biol. 11, 329-341, https://doi.org/10.1038/nrm2882
15. Engelman, J.A., Luo, J. and Cantley, L.C. (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7, 606-619, https://doi.org/10.1038/nrg1879
16. Liu, P., Cheng, H., Roberts, T.M. and Zhao, J.J. (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov. 8, 627-644, https://doi.org/10.1038/nrd2926
17. Houten, S.M. and Wanders, R.J. (2010) A general introduction to the biochemistry of mitochondrial fatty acid beta-oxidation. J. Inherit. Metab. Dis. 33, 469-477, https://doi.org/10.1007/s10545-010-9061-2
18. Bartlett, K. and Eaton, S. (2004) Mitochondrial beta-oxidation. Eur. J. Biochem. 271, 462-469, https://doi.org/10.1046/j.1432-1033.2003.03947.x
19. Sack, M.N., Rader, T.A., Park, S., Bastin, J., McCune, S.A. and Kelly, D.P. (1996) Fatty acid oxidation enzyme gene expression is downregulated in the failing heart. Circulation 94, 2837-2842, https://doi.org/10.1161/01.CIR.94.11.2837
20. Marci, M. and Ajovalasit, P. (2009) Medium-chain acyl-CoA dehydrogenase deficiency in an infant with dilated cardiomyopathy. Cardiol. Res. Pract. 2009, 281389, https://doi.org/10.4061/2009/281389
21. Wiles, J.R., Leslie, N., Knilans, T.K. and Akinbi, H. (2014) Prolonged QTc interval in association with medium-chain acyl-coenzyme A dehydrogenase deficiency. Pediatrics 133, e1781-e1786, https://doi.org/10.1542/peds.2013-1105
22. Tolwani, R.J., Hamm, D.A., Tian, L., Sharer, J.D., Vockley, J., Rinaldo, P. et al. (2005) Medium-chain acyl-CoA dehydrogenase deficiency in gene-targeted mice. PLoS Genet. 1, e23, https://doi.org/10.1371/journal.pgen.0010023
23. Bernardo, B.C., Nguyen, S.S., Gao, X.M., Tham, Y.K., Ooi, J.Y.Y., Patterson, N.L. et al. (2016) Inhibition of miR-154 protects against cardiac dysfunction and fibrosis in a mouse model of pressure overload. Sci. Rep. 6, 22442, https://doi.org/10.1038/srep22442
24. Bernardo, B.C., Nguyen, S.S., Winbanks, C.E., Gao, X.-M., Boey, E.J.H., Tham, Y.K. et al. (2014) Therapeutic silencing of miR-652 restores heart function and attenuates adverse remodeling in a setting of established pathological hypertrophy. FASEB J. 28, 5097-5110, https://doi.org/10.1096/fj.14-253856
25. Gao, X.-M., Kiriazis, H., Moore, X.-L., Feng, X.-H., Sheppard, K., Dart, A. et al. (2005) Regression of pressure overload-induced left ventricular hypertrophy in mice. Am. J. Physiol. Heart Circ. Physiol. 288, H2702-H2707, https://doi.org/10.1152/ajpheart.00836.2004
26. Gregorevic, P., Blankinship, M.J., Allen, J.M., Crawford, R.W., Meuse, L., Miller, D.G. et al. (2004) Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10, 828-834, https://doi.org/10.1038/nm1085
27. Yamamoto, S., Yang, G.P., Zablocki, D., Liu, J., Hong, C., Kim, S.J. et al. (2003) Activation of Mst1 causes dilated cardiomyopathy by stimulating apoptosis without compensatory ventricular myocyte hypertrophy. J. Clin. Invest. 111, 1463-1474, https://doi.org/10.1172/JCI17459
28. Sapra, G., Tham, Y.K., Cemerlang, N., Matsumoto, A., Kiriazis, H., Bernardo, B.C. et al. (2014) The small-molecule BGP-15 protects against heart failure and atrial fibrillation in mice. Nat. Commun. 5, 5705, https://doi.org/10.1038/ncomms6705
29. Shioi, T., Kang, P.M., Douglas, P.S., Hampe, J., Yballe, C.M., Lawitts, J. et al. (2000) The conserved phosphoinositide 3-kinase pathway determines heart size in mice. EMBO J. 19, 2537-2548, https://doi.org/10.1093/emboj/19.11.2537
30. Bernardo, B.C., Gao, X.M., Winbanks, C.E., Boey, E.J., Tham, Y.K., Kiriazis, H. et al. (2012) Therapeutic inhibition of the miR-34 family attenuates pathological cardiac remodeling and improves heart function. Proc. Natl. Acad. Sci. U.S.A. 109, 17615-17620, https://doi.org/10.1073/pnas.1206432109
31. Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T. et al. (2012) Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676-682, https://doi.org/10.1038/nmeth.2019
32. Bernardo, B.C., Ooi, J.Y.Y. and McMullen, J.R. (2012) The yin and yang of adaptive and maladaptive processes in heart failure. Drug Discov. Today Ther. Strateg. 9, e163-e172
33. Bernardo, B.C., Weeks, K.L., Pretorius, L. and McMullen, J.R. (2010) Molecular distinction between physiological and pathological cardiac hypertrophy: experimental findings and therapeutic strategies. Pharmacol. Ther. 128, 191-227, https://doi.org/10.1016/j.pharmthera.2010.04.005
34. Tham, Y.K., Bernardo, B.C., Ooi, J.Y., Weeks, K.L. and McMullen, J.R. (2015) Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets. Arch. Toxicol. 89, 1401-1438, https://doi.org/10.1007/s00204-015-1477-x
35. Weeks, K.L. and McMullen, J.R. (2011) The Athlete's heart vs. the failing heart: can signaling explain the two distinct outcomes? Physiology 26, 97-105, https://doi.org/10.1152/physiol.00043.2010
36. DeBosch, B., Treskov, I., Lupu, T.S., Weinheimer, C., Kovacs, A., Courtois, M. et al. (2006) Akt1 is required for physiological cardiac growth. Circulation 113, 2097-2104, https://doi.org/10.1161/CIRCULATIONAHA.105.595231
37. Riquelme, C.A., Magida, J.A., Harrison, B.C., Wall, C.E., Marr, T.G., Secor, S.M. et al. (2011) Fatty acids identified in the Burmese python promote beneficial cardiac growth. Science 334, 528-531, https://doi.org/10.1126/science.1210558
38. Wall, C.E., Cozza, S., Riquelme, C.A., McCombie, W.R., Heimiller, J.K., Marr, T.G. et al. (2011) Whole transcriptome analysis of the fasting and fed Burmese python heart: insights into extreme physiological cardiac adaptation. Physiol. Genomics 43, 69-76, https://doi.org/10.1152/physiolgenomics.00162.2010
39. Locasale, J.W. and Cantley, L.C. (2011) Metabolic flux and the regulation of mammalian cell growth. Cell Metab. 14, 443-451, https://doi.org/10.1016/j.cmet.2011.07.014
40. McMullen, J.R., Shioi, T., Huang, W.-Y., Zhang, L., Tarnavski, O., Bisping, E. et al. (2004) The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase(p110alpha) pathway. J. Biol. Chem. 279, 4782-4793, https://doi.org/10.1074/jbc.M310405200
41. van der Vusse, G.J., Glatz, J.F., Stam, H.C. and Reneman, R.S. (1992) Fatty acid homeostasis in the normoxic and ischemic heart. Physiol. Rev. 72, 881-940, https://doi.org/10.1152/physrev.1992.72.4.881
42. Lehman, J.J. and Kelly, D.P. (2002) Gene regulatory mechanisms governing energy metabolism during cardiac hypertrophic growth. Heart Fail. Rev. 7, 175-185, https://doi.org/10.1023/A:1015332726303
43. He, L., Kim, T., Long, Q., Liu, J., Wang, P., Zhou, Y. et al. (2012) Carnitine palmitoyltransferase-1b deficiency aggravates pressure overload-induced cardiac hypertrophy caused by lipotoxicity. Circulation 126, 1705-1716, https://doi.org/10.1161/CIRCULATIONAHA.111.075978
44. Haynie, K.R., Vandanmagsar, B., Wicks, S.E., Zhang, J. and Mynatt, R.L. (2014) Inhibition of carnitine palymitoyltransferase1b induces cardiac hypertrophy and mortality in mice. Diabetes Obes. Metab. 16, 757-760, https://doi.org/10.1111/dom.12248
45. Shao, D. and Tian, R. (2015) Glucose transporters in cardiac metabolism and hypertrophy. Compr. Physiol. 6, 331-351, https://doi.org/10.1002/cphy.c150016
46. Barger, P.M., Brandt, J.M., Leone, T.C., Weinheimer, C.J. and Kelly, D.P. (2000) Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. J. Clin. Invest. 105, 1723-1730, https://doi.org/10.1172/JCI9056
47. Arany, Z., Novikov, M., Chin, S., Ma, Y., Rosenzweig, A. and Spiegelman, B.M. (2006) Transverse aortic constriction leads to accelerated heart failure in mice lacking PPAR-gamma coactivator 1alpha. Proc. Natl. Acad. Sci. U.S.A. 103, 10086-10091, https://doi.org/10.1073/pnas.0603615103
48. Kolwicz, Jr, S.C., Olson, D.P., Marney, L.C., Garcia-Menendez, L., Synovec, R.E. and Tian, R. (2012) Cardiac-specific deletion of acetyl CoA carboxylase prevents metabolic remodeling during pressure-overload hypertrophy. Circ. Res. 111, 728-738, https://doi.org/10.1161/CIRCRESAHA.112.268128
49. Greenberg, B., Butler, J., Felker, G.M., Ponikowski, P., Voors, A.A., Desai, A.S. et al. (2016) Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial. Lancet 387, 1178-1186, https://doi.org/10.1016/S0140-6736(16)00082-9
50. Hammond, H., Penny, W.F., Traverse, J.H., Henry, T.D., Watkins, M.W., Yancy, C.W. et al. (2016) Intracoronary gene transfer of adenylyl cyclase 6 in patients with heart failure: a randomized clinical trial. JAMA Cardiol. 1, 163-171, https://doi.org/10.1001/jamacardio.2016.0008
51. Chung, E.S., Miller, L., Patel, A.N., Anderson, R.D., Mendelsohn, F.O., Traverse, J. et al. (2015) Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial. Eur. Heart J. 36, 2228-2238, https://doi.org/10.1093/eurheartj/ehv254
52. Hajjar, R.J. and Ishikawa, K. (2017) Introducing genes to the heart-all about delivery. Circ. Res. 120, 33-35, https://doi.org/10.1161/CIRCRESAHA.116.310039
53. Penny, W.F. and Hammond, H.K. (2017) Randomized clinical trials of gene transfer for heart failure with reduced ejection fraction. Hum. Gene Ther. 28, 378-384, https://doi.org/10.1089/hum.2016.166